Preparation and characterization of salt forms of enalapril

Pharmaceutical Development and Technology

Volumn 13, Issue 5, 2008, Pages 345-357

  Kumar, Lokesh ^a   Amin, Aeshna ^a   Bansal, Arvind K ^a  

^a NATIONAL INSTITUTE OF PHARMACEUTICAL EDUCATION AND RESEARCH NIPER   (India)

Author keywords

Enalapril maleate; Preformulation; Salt; Salt selection

Indexed keywords

BENZENESULFONIC ACID; CITRIC ACID; ENALAPRIL; ENALAPRIL BESYLATE; ENALAPRIL CITRATE; ENALAPRIL MALATE; ENALAPRIL MALEATE; ENALAPRIL MESYLATE; ENALAPRIL TARTRATE; ENALAPRIL TOSYLATE; MALIC ACID; MESYLIC ACID; TARTARIC ACID; TOLUENESULFONIC ACID DERIVATIVE; UNCLASSIFIED DRUG;

ARTICLE; CHEMICAL REACTION; CRYSTALLIZATION; DIFFERENTIAL SCANNING CALORIMETRY; DRUG FORMULATION; DRUG MANUFACTURE; DRUG SOLUBILITY; DRUG STABILITY; GAS CHROMATOGRAPHY; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; INFRARED SPECTROSCOPY; MASS SPECTROMETRY; MICROSCOPY; PARAMETER; PHYSICAL CHEMISTRY; PREFORMULATION; PRIORITY JOURNAL; SALT FORMATION; SOLID STATE; TABLET COMPRESSION; THERMOGRAVIMETRY; TITRIMETRY; WETTABILITY; X RAY POWDER DIFFRACTION;

ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; CHEMISTRY, PHARMACEUTICAL; CRYSTALLIZATION; DRUG DESIGN; DRUG STABILITY; ENALAPRIL; SALTS; SOLUBILITY;

EID: 51949100375     PISSN: 10837450     EISSN: 10979867     Source Type: Journal    
DOI: 10.1080/10837450802244686     Document Type: Article

References (25)

1. Berge SM, Bighley LM, Monkhouse DC. Pharmaceutical salts. J. Pharm. Sci. 1977:66(1):1-19.
2. Wermuth CG, Stahl PH. Introduction. In: Stahl PH, Wermuth CG, eds. Handbook of Pharmaceutical Salts: Properties, Selection and Use. Weinheim: Wiley-VCH, Inc: 2002:1-7.
3. Anderson BD, Conradi RA. Predictive relationships in the water solubility of salts of a nonsteroidal anti-inflammatory drug. J. Pharm. Sci. 1985;74(8):815-820.
4. Morris KR, Fakes MG, Thakur AB, Newman AW, Singh AK, Venit JJ, Spagnuolo CJ, Serajuddin ATM. An integrated approach to the selection of optimal salt form for a new drug candidate. Int. J. Pharm. 1994;105(3):209-217.
5. Engel GL, Farid NA, Faul MM, Richardson LA, Winneroski LL. Salt form selection and characterization of LY333531 mesylate monohydrate. Int. J. Pharm. 2000;198(2):239-247.
6. Ip DP, Brenner GS. Enalapril maleate. In: Florey K, ed. Analytical Profiles of Drug Substances. London: Academic Press, Inc: 1987:207-243.
7. Cotton ML, Wu DW, Vadas EB. Drug excipient interaction study of enalapril maleate using thermal analysis and scanning electron microscopy. Int. J. Pharm. 1987:40(1-2):129-142.
8. Omari AMM, Abdelah MK, Badwan AA, Jaber AMY. Effect of the drug-matrix on the stability of enalapril maleate in tablet formulations. J. Pharm. Biomed. Anal. 2001:25(5-6):893-902.
9. Janos F, Bela S, Attila B, Mueller CG, Tamas F, Sandor L, Gabor T. Salts of Enalpril. 2001, WO0132689.
10. Soldato PD. ACE inhibitors nitric salts. 2001. U.S. Patent 6218417.
11. Tong WQ, Whitesell G. In situ salt screening - a useful technique for discovery support and preformulation studies. Pharm. Dev. Technol. 1998;3(2):215-223.
12. Fürer R, Geiger M. A simple method of determining the aqueous solubility of organic substances. J. Pharm. Sci. 1976;8(4):337-344.
13. Carr RL. Classifying flow properties of solids. Chem. Eng. 1965;72:69-72.
14. Carr RL. Evaluation of flow properties of solids. Chem. Eng. 1965;72:163-168.
15. Ueda Y, Kinoshita K, Moroshima T, Yanagida Y, Fuse Y. Process for preparing pharmacologically acceptable salt of N-(1(S)-ethoxycarbonyl-3- phenylpropyl)-L-alanyl amino acids. 2002. U.S. Patent 6335453.
16. Balbach S, Korn C. Pharmaceutical evaluation of early development candidates "the 100 mg-approach". Int. J. Pharm. 2004;275(1-2):1-12.
17. ICH Harmonised Tripartite Guideline: Note for guidance on impurities - residual solvents Q3C (R3); 2005. International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use http://www.ich.org/LOB/media/MEDIA423.pdf (accessed Nov. 2007).
18. Callahan JC, Cleary JW, Elefant M, Kaplan G, Kensler T, and Nash RA. Equilibrium moisture content of pharmaceutical excipients. Drug Dev. Ind. Pharm. 1982;8(3):355-369.
19. Bhattachar SN, Deschenes LA, Wesley JA. Solubility: It's not just for physical chemists. Drug Discov. Today 2006;11(21-22):1012-1018.
20. Stephenson GA. Applications of X-ray powder diffraction in the pharmaceutical industry. Rigaku J. 2005;22(1):2-15.
21. Karjalainen M, Airaksinen S, Rantanen J, Aaltonen J, Yliruusi J. Characterization of polymorphic solid-state changes using variable temperature x-ray powder diffraction. J. Pharm. Biomed. Anal. 2005;39(1-2):27-32.
22. de Villiers MM, Terblanche RJ, Liebenberg W, Swanepoel E, Dekker TG, Song M. Variable-temperature x-ray powder diffraction analysis of the crystal transformation of the pharmaceutically preferred polymorph C of mebendazole. J. Pharm. Biomed. Anal. 2005;38(3):435-441.
23. Armstrong NA, Haines-Nutt RF. Elastic recovery and surface area changes in compacted powder systems. J. Pharm. Pharmacol. 1972;24:135P-136.
24. Antikainen O, Yliruusi J. Determining the compression behavior of pharmaceutical powders from the force-distance compression profile. Int. J. Pharm. 2003;252(1-2): 253-261.
25. Sun C, Grant DJW. Influence of elastic deformation of particles on Heckel analysis. Pharm. Dev. Technol. 2001:6(2):193-200.